Meningitis

• Robbins & Kumar Basic Pathology, p. 833
• Goldman-Cecil Medicine, p. 3997

Classification

Etiology by Age Group

• Neonates (0-6 weeks): Escherichia coli, Group B streptococci (Streptococcus agalactiae)
• Infants and children: Neisseria meningitidis (most common in children/young adults); Haemophilus influenzae type b incidence has sharply declined since the Hib vaccine
• Adults <50 yrs: S. pneumoniae, N. meningitidis
• Adults >50 yrs / immunocompromised / elderly: S. pneumoniae, Listeria monocytogenes
• Post-neurosurgery / trauma: Coagulase-negative staphylococci, S. aureus, Cutibacterium acnes, gram-negative rods (including Pseudomonas aeruginosa)

Pathophysiology

1. Increased permeability of the blood-brain barrier
2. Cerebral vasculitis
3. Cerebral edema
4. Raised intracranial pressure (ICP)
5. Reduced cerebral blood flow → cerebral hypoxia

Clinical Features

• Subtle presentations are common - especially in the immunocompromised and elderly, where altered mental status may be the only finding
• Neonates may present with a bulging fontanelle, behavioral changes, decreased tone, or poor feeding
• All neonates with suspected infection should have a lumbar puncture

• Waterhouse-Friderichsen syndrome: bilateral adrenal hemorrhage with DIC and purpura
• Endotoxic shock and vascular collapse

• Cerebral venous thrombosis (~1% of cases) - presents as new seizures, altered sensorium, focal deficits
• Hearing loss (especially with H. influenzae and pneumococcal meningitis)

CSF Findings

Management

1. Stabilization

• Ensure CNS oxygenation and perfusion
• If severely elevated ICP: endotracheal intubation, mannitol, hypertonic saline, maintain eucapnia

2. Empiric Antibiotics

3. Corticosteroids

• Reduces mortality in pneumococcal meningitis
• Reduces hearing loss in H. influenzae meningitis
• This benefit has only been demonstrated in high-income countries
• Discontinue if Listeria is identified - dexamethasone is associated with worse outcomes in Listeria CNS infection

Viral Meningitis

Tuberculous Meningitis

Fungal Meningitis

Differential Diagnosis

• Subarachnoid hemorrhage (SAH) - blood is meningeal irritant; differentiated by CT/LP; patients lack infectious prodrome
• Brain abscess - often focal deficits, fever may be mild/absent
• Nonconvulsive status epilepticus - altered mental status, especially with seizure history
• CNS malignancy / carcinomatous meningitis
• Autoimmune/drug-induced meningitis
• Cerebral venous thrombosis

Complications

• Hearing loss (most common long-term complication)
• Hydrocephalus (especially in TB and neonatal meningitis)
• Cerebral venous thrombosis
• Subdural empyema
• Waterhouse-Friderichsen syndrome (meningococcal)
• Septic shock / DIC
• Residual neurologic deficits - highest rates with pneumococcal meningitis

Prevention (Vaccines)

Orris vs ChatGPT

What I do differently

Where ChatGPT has advantages

• Larger general knowledge base and broader training data
• More polished at creative writing, coding, and casual conversation
• GPT-4o is fast and very capable across a wide range of tasks
• Has image generation, voice mode, and deep research features built into its ecosystem
• Better known and more widely tested in the wild

The honest summary

1. It hasn't been officially announced yet as of today (July 12, 2026)
2. It may not exist - OpenAI doesn't always use sequential ".5" versioning. After GPT-4 they went to GPT-4o, GPT-4.5, and GPT-5, not necessarily following a predictable pattern
3. You may be thinking of a different model - OpenAI has released several models under different names (o3, o4-mini, GPT-5, etc.)

Orris vs GPT-5.6 (Sol/Terra/Luna)

• Sol - flagship, highest capability
• Terra - mid-range, strong cost-performance
• Luna - fast, cheapest tier

Where GPT-5.6 is ahead of me

Where I hold my own

The honest bottom line

1. Screening for Disease

Definition

"The search for unrecognized disease or defect by means of rapidly applied tests, examinations or other procedures in apparently healthy individuals."

• Park's Textbook of Preventive and Social Medicine

1. Capable of wide application
2. Relatively inexpensive
3. Requires little physician time (a technician can administer the test; the physician interprets it)

Types of Screening

a. Mass Screening

• Screening of a whole population or large subgroup irrespective of individual risk level
• Example: Chest X-ray for tuberculosis in an entire community
• Limitation: Indiscriminate mass screening has little justification unless backed by suitable treatment that reduces the duration or alters the outcome of illness. Evidence has shown mass screening does not always reduce mortality and can increase cost without observable benefit.

b. High-Risk (Selective) Screening

• Applied selectively to groups defined as high-risk based on epidemiological research
• More productive and economical than mass screening
• Examples:
  • Screening for cervical cancer in lower socioeconomic groups (higher incidence)
  • Screening family members of diabetic or hypertensive patients
  • Screening for elevated serum cholesterol in those with family history of coronary heart disease
• Epidemiologists have extended this concept to screening for risk factors (e.g., elevated blood pressure, raised serum cholesterol) which antedate actual disease

c. Multiphasic Screening

• Application of two or more screening tests in combination to a large number of people at one time
• May include: health questionnaire, clinical examination, blood/urine chemistry, lung function tests, audiometry, visual acuity measurement
• Example: Combined HIV + syphilis + hepatitis B screening at a single visit
• Limitation: Randomized controlled studies in the UK and USA showed multiphasic screening has NOT shown benefit in mortality or morbidity reduction; it has increased costs. Most tests in multiphasic screening programmes have not been validated individually.

Uses of Screening

a. Case Detection (Prescriptive Screening)

• Presumptive identification of unrecognized disease, not arising from the patient's request
• People are screened primarily for their own benefit
• Examples: Neonatal PKU screening, bacteriuria in pregnancy, breast cancer screening, diabetes mellitus detection
• Since disease detection is initiated by medical/public health personnel, they carry special obligation to ensure early treatment is started

b. Control of Disease

• Screening aimed at interrupting transmission of communicable diseases
• Example: Contact tracing and screening in tuberculosis, STI screening, screening blood donors for HIV/hepatitis

c. Research

• Screening used for epidemiological research purposes
• Establishes prevalence of disease/risk factors in a community
• Generates data to guide public health policy

d. Educational Opportunities

• Screening programmes (e.g., for diabetes) provide opportunities for creating public awareness and educating health professionals about disease

Criteria for Selection of Disease (Wilson-Jungner WHO Criteria)

1. The condition should be an important health problem (significant morbidity/mortality)
2. There should be a recognizable latent or early symptomatic stage
3. The natural history of the condition should be adequately understood
4. The condition should have a detectable preclinical phase (a "lead time")

Criteria for Selection of the Screening Test

2. Levels of Prevention

Level 0: Primordial Prevention

• This is primary prevention in its purest sense
• Many adult diseases (obesity, hypertension, coronary artery disease) have early origins in childhood, when lifestyles are formed
• Main intervention: Individual and mass education
• Target: Children and young people, before harmful lifestyles are adopted
• Examples:
  • Discouraging children from smoking before the habit forms
  • National dietary guidelines to prevent obesity in a population where it is not yet prevalent
  • Promoting physical activity in school curricula

Level 1: Primary Prevention

"Action taken prior to the onset of disease, which removes the possibility that a disease will ever occur."

• Intervenes in the pre-pathogenesis phase
• Concerned with the concept of "positive health" - enabling individuals to lead socially and economically productive lives
• Two main approaches:
  • Population (mass) strategy: Directed at the whole population to reduce average risk (e.g., reducing average blood pressure by reducing salt in food supply)
  • High-risk strategy: Targets individuals at special risk identified by clinical methods

• Immunization against polio, measles, tetanus
• Oral rehydration therapy promotion
• Fluoridation of water supply (prevents dental caries)
• Use of condoms (prevents HIV/STIs)
• Antismoking campaigns
• Safe food, water, and sanitation

Level 2: Secondary Prevention

"Action which halts the progress of a disease at its incipient stage and prevents complications."

• Specific interventions: early diagnosis (screening tests, case-finding) + adequate treatment
• Attempts to arrest the disease process before irreversible pathological changes occur
• Also reduces communicability of infectious diseases

• Pap smear for early detection of cervical cancer
• Blood pressure measurement to detect hypertension
• Mammography for early breast cancer
• Blood glucose testing for diabetes
• Chest X-ray/Mantoux test for early tuberculosis
• Treating hypertension before a stroke occurs

Level 3: Tertiary Prevention

"All measures available to reduce or limit impairments and disabilities, minimize suffering caused by existing departures from good health and to promote the patient's adjustment to irremediable conditions."

• Intervenes in the late pathogenesis phase
• Includes both treatment of established disease (to prevent further sequelae) and rehabilitation
• Modern rehabilitation includes psychosocial, vocational, and medical components

• Physiotherapy after a stroke to reduce disability
• Prosthetic limbs after amputation in a diabetic patient
• Colostomy care after colorectal cancer surgery
• Psychiatric rehabilitation for chronic schizophrenia
• Vocational retraining after spinal cord injury

Summary Table: Levels of Prevention

3. Sensitivity and Specificity of a Screening Test

The 2×2 Contingency Table

Sensitivity

• Also called the True Positive Rate
• Its inverse (1 - Sensitivity) = False Negative Rate
• A test with 90% sensitivity: correctly identifies 90 out of 100 diseased patients; misses 10 (false negatives)
• High sensitivity = few false negatives
• A highly sensitive test is used to rule OUT disease (mnemonic: SnNOut - Sensitive test, Negative result, rules Out)

Specificity

• Also called the True Negative Rate
• Its inverse (1 - Specificity) = False Positive Rate
• A test with 90% specificity: correctly identifies 90 out of 100 disease-free patients as negative; 10 are falsely called positive
• High specificity = few false positives
• A highly specific test is used to rule IN disease (mnemonic: SpPIn - Specific test, Positive result, rules In)

Worked Example (Henry's Clinical Diagnosis, p. 119):

• Sensitivity = 196/(196+4) × 100 = 98%
• Specificity = 180/(180+20) × 100 = 90%
• Positive Predictive Value (PPV) = 196/(196+20) × 100 = 91%
• Negative Predictive Value (NPV) = 180/(180+4) × 100 = 98%

Sensitivity-Specificity Trade-off

• Lowering the cutoff → Increases sensitivity (catches more true cases) but decreases specificity (more false positives)
• Raising the cutoff → Increases specificity (fewer false positives) but decreases sensitivity (more false negatives)

Predictive Values (Affected by Prevalence)

4. Difference Between Screening Test and Diagnostic Test

Key principle: A positive screening test does NOT mean the person has the disease - it only means they are suspects who require diagnostic testing. A positive diagnostic test IS the basis for treatment.